Palle Christophersen
Founder chez SANA AB
Fortune : 157 694 $ au 31/03/2024
Profil
Palle Christophersen is the founder of Saniona AB, which was founded in 2011.
He holds the title of Executive Vice President-Research at Saniona AB.
Dr. Christophersen is currently the Chief Scientific Officer at Saniona A.
Dr. Christophersen previously worked at NTG Nordic Transport Group A from 1991 to 2012, where he held the title of Vice President & Director-Vitro Pharmacology.
Dr. Christophersen obtained a doctorate degree from the University of Copenhagen.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SANIONA AB
0,79% | 31/12/2022 | 874 571 ( 0,79% ) | 157 694 $ | 31/03/2024 |
Postes actifs de Palle Christophersen
| Sociétés | Poste | Début |
|---|---|---|
| SANA AB | Founder | 01/01/2011 |
Saniona A/S
 Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Palle Christophersen
| Sociétés | Poste | Fin |
|---|---|---|
| NTG NORDIC TRANSPORT GROUP A/S | Corporate Officer/Principal | 01/01/2012 |
Formation de Palle Christophersen
| University of Copenhagen | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NTG NORDIC TRANSPORT GROUP A/S | Transportation |
| SANA AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Commercial Services |
